Manitex Capital Inc. affiliate, Ortho Regenerative Technologies Inc., announces the appointment of Dr. Ed Margerrison as President and CEO

KIRKLAND, QC, Dec. 9, 2015 /CNW Telbec/ - Manitex Capital Inc. ("Manitex") affiliate, Ortho Regenerative Technologies Inc. ("Ortho RTi"), a Canadian orthopaedic biotechnology company, announced today that it has appointed Dr. Ed Margerrison as President and CEO.

"Ortho RTi is entering the next phase of its development and the company sought out a leader with the background to be able to bring its technology into the clinic with human trials and lead the organization towards commercialization" said Manitex Chairman and CEO Steve Saviuk. "Ed has the unique combination of knowledge and experience that we were looking for".

"I am very pleased to be joining Ortho RTI at this exciting stage in its development. Ortho RTi's technology holds the promise to make meaningful differences to early stage soft tissue injuries and prevent further joint damage for patients around the globe. Our focus in the immediate future will be to move the technology into the clinic and prove that the unique biopolymer platform can meet these expectations."

Dr Margerrison is an industry veteran with 25 years experience in the orthopaedic industry. A Ph.D in molecular biology, Dr Margerrison most recently led the biologics division of Zimmer Inc., a multi-billion dollar leader in the orthopaedic market. Prior to this, Dr Margerrison had spent 14 years at Smith & Nephew Orthopaedics, leading and growing the biologics division through development and acquisition activities.

Caution regarding forward-looking statements

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

About Ortho Regenerative Technologies Inc.

Ortho RTi is a Canadian orthopaedic biotechnology company dedicated to the development of medical devices to treat unmet needs in the orthopaedic market. Based on a proprietary biopolymer platform, the company is developing new regenerative treatments for soft tissue tears in the shoulder and knee, both with few productive options for repair.

About Manitex Capital Inc.

Manitex Capital Inc. specializes in the acquisition of equity interests in emerging life science companies and actively participates in their management. Manitex currently has 12,561,276 common shares outstanding which are quoted for trading on the TSX Venture Exchange.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

SOURCE Ortho RTI

Manitex Capital Inc., Steve Saviuk, Chairman and CEO Tel.: [phone], [email protected]